Black Diamond Therapeutics
CompanyUnited States
Black Diamond Therapeutics develops one asset, in phase 2 (Silevertinib in non-small cell lung cancer with EGFR non-classical mutations). Mostly small molecule acting on EGFR; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $134M
- 1
- Trial
- 1
- Signal
Pipeline
1Inhibits mutant EGFR signaling to suppress tumor growth.
Phase 2, Small molecule, EGFR, non-small cell lung cancer with EGFR non-classical mutations, non-small cell lung cancer (Clinical, no phase)
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Funding rounds and grants3
- Deals2
- Signals1
- Similar companies6